Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Spanish Breast Cancer Research Group (GEICAM)

Status and phase: Terminated; Phase 3

Conditions: Breast Cancer

Treatments: Drug: Fulvestrant; Drug: Anastrozole

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00543127

GEICAM/2006-10

2007-003417-14 (EudraCT Number)

Details and patient eligibility

About

Postmenopausal women with hormone receptor positive and negative Her2 tumours.

Before randomization, the patients will be stratified according to the center, positive nodes (0 vs. 1-3 vs. ≥4), previous chemotherapy (yes vs no) and hormonal receptors status.

Full description

It is expected that disease-free survival for patients receiving Anastrozole alone for 5 years will be up to 90%. An increase of 3% in disease-free survival (DFS) is expected in the arm of Fulvestrant plus Anastrozole, i.e a DFS of up to 93%. They will be required 1358 patients per treatment group (i.e, 2716 patients in total) to give 80% power, alfa bilateral 0.05, and OR 0.6888. Assuming 5% screening failures 2852 patients are required to enter the study. In Jun-2010 the recruitment was stopped due to lack of support of the financier based on the result of Faslodex® and Arimidex® in Combination Trial (FACT-trial), comparing Fulvestrant + Anastrozole vs Anastrozole alone in 1st relapse showed no difference in time to progression at more than 40 months follow-up.

Enrollment: 870 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Histological documentation of breast cancer.

2. Stage I, II, IIIA and IIIC* invasive breast cancer. One of these two characteristics must be fulfilled:

   • N+
   • T > 1cm *Eligible patients T1-T3 and pN3a (patients with metastasis in infraclavicular nodes would not be eligible)

3. Local treatment with curative intention:

   • mastectomy or tumour excision with free margins + radiotherapy
   • axillary lymphadenectomy or sentinel node biopsy

4. Positive hormone receptors (Estrogen Receptor [ER]+ and/or Progesterone Receptor [PR]+) in primary tumour tissue as measured by a central laboratory

5. Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, defined as immunohistochemistry (IHC) 0 or 1+ or negative fluorescence in situ hybridization (FISH) (in the event of IHC 2+ or 3+)

6. Postmenopausal women, defined as women meeting any of the following criteria:

   • Age ≥ 60 years
   • Age ≥ 45 years with amenorrhea ≥ 12 months in the moment of breast cancer diagnosis and an intact uterus
   • Prior bilateral ovariectomy
   • In case previous hysterectomy, follicle stimulating hormone (FSH) and estradiol levels within the postmenopausal range (using local laboratory ranges)* * In patients previously treated with a luteinizing hormone releasing hormone (LH-RH) analogue, the last extended release formulation should have been administered more than 6 months before randomisation, and menses must not have reappeared.

7. A World Health Organization (WHO) performance status of 0, 1, or 2.

8. Age > 18 years

Exclusion criteria

1. Presence of metastatic disease or bilateral invasive cancer

2. ER and Progesterone Receptor (PR) negative breast cancer

3. HER2-positive breast cancer, defined as FISH+

4. Treatment with a non-approved or experimental drug within 4 months of randomisation

5. Current malignancy or previous malignancy in the past 5 years (other that breast cancer or basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix)

6. Pregnant or nursing patients

7. Any of the following laboratory values within 3 months of randomisation:

   • Platelets < 100 x 109/L

   • Total bilirubin > 1.5 x Upper limit of reference range (ULRR)**

     ** Patients with documented Gilbert syndrome may be included in this trial

   • Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 2.5 x ULRR

   • A history of:

   • hemorrhagic diathesis (i.e. Disseminated Intravascular Coagulation [DIC], coagulation factor deficiency) or

   • long-term anticoagulant treatment (except for anti-platelet aggregants and low-dose warfarin; see section 3.7)

8. A history of hypersensitivity to the active ingredient or inactive excipients of fulvestrant, aromatase inhibitors, or castor oil

9. Any concomitant severe disease advising against patient participation in the trial o that may jeopardize compliance with the trial protocol, such as uncontrolled heart disease, uncontrolled diabetes mellitus, or uncontrolled severe infections

10. Hormone replacement therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

870 participants in 2 patient groups

Fulvestrant + Anastrozole

Experimental group

Description:

Fulvestrant loading dose regimen will consist of two 5 ml intramuscular injections on day 0 (500 mg), 250 mg single injection on days 14 and 28, and 250 mg single injection every 28 days thereafter for 3 years plus Anastrozole 1 mg PO once daily for 5 years

Treatment:

Drug: Anastrozole

Drug: Fulvestrant

Anastrozole

Active Comparator group

Description:

Anastrozole 1 mg will be administered orally as one tablet daily for 5 years.

Treatment:

Drug: Anastrozole